Last $0.24 USD
Change Today +0.087 / 58.00%
Volume 43.7K
As of 8:10 PM 02/27/15 All times are local (Market data is delayed by at least 15 minutes).

lixte biotechnology holdings (LIXT) Key Developments

Lixte Biotechnology Holdings, Inc. Announces Expansion of Clinical Sites for its Phase I Trial of Lead Anti-Cancer Compound, LB-100

Lixte Biotechnology Holdings, Inc. announced that the number of clinical sites where its Phase I trial of Lixte's lead compound, LB-100, is being conducted, has been expanded from 1 to 5 institutions. The company said that, the initial trial was planned to be completed at a single site. Accrual of patients, however, was slower than projected. The recent addition of 4 more active clinical oncologic research sites has already enhanced the rate of accrual with patient entry at the 5th planned dose escalation to be completed this month. The original time-line for completion of both parts of this 2-part trial was June 30, 2015. The estimated time to completion of Part 1 of the trial, the determination of dose and safety of LB-100 alone (maximum tolerated dose (MTD)), is now projected to be the 2nd quarter of 2015 and completion of Part 2, determination of the MTD of LB-100 combined with docetaxel, the 2nd quarter of 2016. The estimated cost for completion of both Part 1 and 2 is $2,615,000 versus the original projection of $2,038,000. The ultimate cost may vary depending on such factors as the number and rate of accrual of patients. The increase in cost is for management of the study, predominantly the monitoring of the additional new sites over a longer period of time.

Lixte Biotechnology Holdings, Inc. Presents at 33rd Annual J.P. Morgan Healthcare Conference, Jan-12-2015

Lixte Biotechnology Holdings, Inc. Presents at 33rd Annual J.P. Morgan Healthcare Conference, Jan-12-2015 . Venue: Westin St. Francis Hotel, San Francisco, California, United States.

Lixte Biotechnology Holdings, Inc. Presents at 7th annual Biotech Showcase Conference 2015, Jan-12-2015

Lixte Biotechnology Holdings, Inc. Presents at 7th annual Biotech Showcase Conference 2015, Jan-12-2015 . Venue: Parc 55 Wyndham San, Francisco - Union Square, San Francisco, CA 94102, United States.

Lixte Biotechnology Holdings, Inc. Presents at 14th Annual Biotech in Europe Forum for Global Partnering & Investment, Sep-30-2014 04:50 PM

Lixte Biotechnology Holdings, Inc. Presents at 14th Annual Biotech in Europe Forum for Global Partnering & Investment, Sep-30-2014 04:50 PM. Venue: Congress Center Basel, MCH Messe Schweiz (Basel) AG, CH-4005 Basel, Switzerland.

Lixte Biotechnology Holdings, Inc. Presents at Rodman & Renshaw 16th Annual Global Investment Conference, Sep-10-2014 03:45 PM

Lixte Biotechnology Holdings, Inc. Presents at Rodman & Renshaw 16th Annual Global Investment Conference, Sep-10-2014 03:45 PM. Venue: New York Palace Hotel – 455 Madison Avenue, New York, NY 10022, United States.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
LIXT:US $0.24 USD +0.087

LIXT Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for LIXT.
View Industry Companies
 

Industry Analysis

LIXT

Industry Average

Valuation LIXT Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 11.5x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact LIXTE BIOTECHNOLOGY HOLDINGS, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.